Bristol-Myers Squibb Company (BMY)

In the past six months, Bristol Myers Squibb's stock has been impacted by acquisitions and a credit rating downgrade, Q4 and full-year 2025 financial results, a dividend increase, stock price fluctuations, and patent cliff concerns.

Information regarding specific demand seasonality for Bristol Myers Squibb Co. products and services is not explicitly detailed in the provided search results. The demand for pharmaceutical products is generally driven by disease prevalence, treatment guidelines, and patient access, which typically do not exhibit strong seasonal fluctuations in the same way consumer goods might.

Bristol Myers Squibb Co. is a global biopharmaceutical company focused on discovering, developing, and selling innovative medicines for serious diseases, operating within the Healthcare sector. Its major products include Eliquis, Opdivo, Revlimid, Orencia, Pomalyst/Imnovid, Yervoy, and Reblozyl.

Bristol Myers Squibb operates globally, with 71% of its 2024 revenues coming from the United States. It has R&D hubs and manufacturing facilities in the U.S., Europe, and Asia Pacific regions.

Bristol Myers Squibb's brand reputation has been influenced by its strategic focus on innovation and acquisitions, alongside ongoing challenges related to patent expirations and past legal issues. The company is recognized for its advancements in chemistry, pharmacy, and biology.

Bristol Myers Squibb is predominantly owned by institutional investors, who hold approximately 75% of the company's shares. The top 10 institutional investors collectively own 39% of the company. Individual investors and company insiders hold a smaller percentage, with insiders collectively holding under 1% of the shares.